Back

Targeting Circulating FABP4 Ameliorates Obesity-Associated Hepatic Steatosis

Jiang, X.; Avellino, A.; Yu, J.; Liu, S.; Wang, Z.; Han, X.; Thakkar, H.; Shilyansky, J.; Xu, Z.; Schnicker, N.; Chaurasia, B.; Hao, J.; Sugg, S. L.; Li, B.

2026-01-26 pathology
10.64898/2026.01.24.701451 bioRxiv
Show abstract

Obesity is a major driver of hepatic steatosis, yet the molecular link between excess adiposity and hepatocellular lipid accumulation remains incompletely defined. Here, we identify circulating fatty acid-binding protein 4 (FABP4) as a key mediator of adipocyte-hepatocyte lipid crosstalk in obesity. Analyses of human liver specimens and mouse models reveal aberrant accumulation of FABP4 protein--but not transcript--in hepatocytes during steatosis, indicating an extrinsic source. Genetic deletion of FABP4, specifically in adipocytes, protects against high fat diet-induced hepatic steatosis without altering obesity or systemic lipid levels. Mechanistically, circulating FABP4 directly binds to hepatocytes, facilitating free fatty acid uptake. Furthermore, we developed a high-affinity humanized monoclonal antibody that selectively neutralizes circulating FABP4, blocks hepatocyte binding, suppresses fatty acid uptake, and markedly attenuates hepatic steatosis in multiple obese mouse models. These findings establish circulating FABP4 as a pathogenic lipid chaperone and a promising therapeutic target for obesity-associated hepatic steatosis. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=180 SRC="FIGDIR/small/701451v1_ufig1.gif" ALT="Figure 1"> View larger version (61K): org.highwire.dtl.DTLVardef@200778org.highwire.dtl.DTLVardef@ca7204org.highwire.dtl.DTLVardef@1037674org.highwire.dtl.DTLVardef@55c680_HPS_FORMAT_FIGEXP M_FIG C_FIG HighlightsO_LIHepatocytic accumulation of extrinsic FABP4 links adiposity to liver lipid deposition. C_LIO_LISpecific deletion of FABP4 in adipocytes prevents hepatic steatosis without affecting systemic lipid levels or obesity. C_LIO_LICirculating FABP4 derived from adipocytes directly binds hepatocytes to facilitate free fatty acid transfer. C_LIO_LIBlocking circulating FABP4 with a high-affinity anti-FABP4 monoclonal antibody inhibits hepatocyte lipid uptake and attenuates steatosis in multiple obese mouse models. C_LI

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Cell Reports
1338 papers in training set
Top 0.2%
21.7%
2
Journal of Clinical Investigation
164 papers in training set
Top 0.1%
11.9%
3
Nature Communications
4913 papers in training set
Top 20%
9.7%
4
Nature
575 papers in training set
Top 5%
6.1%
5
Nature Metabolism
56 papers in training set
Top 0.3%
6.1%
50% of probability mass above
6
Neuron
282 papers in training set
Top 3%
4.7%
7
Cell Discovery
54 papers in training set
Top 1%
3.5%
8
Protein & Cell
25 papers in training set
Top 0.7%
3.1%
9
Cell Stem Cell
57 papers in training set
Top 0.6%
3.0%
10
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 27%
2.3%
11
The EMBO Journal
267 papers in training set
Top 0.9%
2.3%
12
eLife
5422 papers in training set
Top 37%
2.0%
13
Science Translational Medicine
111 papers in training set
Top 3%
1.6%
14
The Lancet Infectious Diseases
71 papers in training set
Top 2%
1.6%
15
Molecular Cell
308 papers in training set
Top 7%
1.6%
16
Cell Chemical Biology
81 papers in training set
Top 2%
1.3%
17
Developmental Cell
168 papers in training set
Top 11%
0.9%
18
Gastroenterology
40 papers in training set
Top 2%
0.8%
19
Cell Reports Medicine
140 papers in training set
Top 8%
0.8%
20
JCI Insight
241 papers in training set
Top 8%
0.7%
21
Immunity
58 papers in training set
Top 4%
0.7%
22
Cell Genomics
162 papers in training set
Top 7%
0.7%
23
Cell Metabolism
49 papers in training set
Top 3%
0.6%
24
Metabolism
14 papers in training set
Top 0.6%
0.6%
25
Cancer Research
116 papers in training set
Top 4%
0.6%